Nippon India Pharma Fund Direct Growth NAV today
AMFI: 118759ISIN: INF204K01I50MUTF_IN: NIPP_INDI_PHAR_12HWAIJNippon India Mutual FundSectoral / Thematic funds
Formerly Reliance Pharma Fund
NAV ₹622.2151up ₹10.76 (1.76%)
NAV for 29 Oct 2026, against 27 Oct 2026. Declared once a day.
Other plans: Regular Growth ₹552.3717, 1.76% · Regular IDCW ₹119.2814 · Direct IDCW ₹170.2871
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month. Assets under management in the glossary
- ₹9,166 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it. Total expense ratio: how it is worked out
- 0.99%26 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought. Exit load in the glossary
- 1%if sold within 1 month
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot pull the fund's P/E down. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted. P/E in the glossary
- 38.730 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. Riskometer in the glossary
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures. Holdings in the glossary
- 3630 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer. Launch date in the glossary
- 5 Jun 2004
Nippon India Pharma Fund returns
Direct Growth plan
Over each window to 29 Oct 2026
| Over | Direct GrowthTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). Trailing return: how it is worked out | Regular Growth | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. Benchmark in the glossary | Rank in categoryRank in category. The fund's place among the funds of its category with a return over the same window, highest return first. Rank in category in the glossary | Category medianCategory median. The middle return of the funds in the category over the same window: half returned more, half less. Category median in the glossary | Middle halfMiddle half of the category. The returns of the fund a quarter of the way down the category and the fund a quarter of the way up, over the same window: half the category's funds returned between the two. Middle half of the category in the glossary |
|---|---|---|---|---|---|---|
| 1 week | +4.66% | +4.65% | – | – | – | – |
| 1 month | −2.93% | −3.00% | – | 176 of 254 | −1.85% | −3.3% to −0.9% |
| 3 months | −3.10% | −3.30% | – | 81 of 250 | −4.99% | −6.5% to −2.1% |
| 6 months | +7.22% | +6.77% | – | 54 of 250 | −0.82% | −3.7% to +6.2% |
| 1 year | +8.00% | +7.07% | +16.77%to 30 Sep 2026 | 42 of 231 | −3.20% | −8.1% to +3.8% |
| 3 years | +18.37% | +17.32% | +21.25%to 30 Sep 2026 | 36 of 141 | +13.29% | +9.5% to +18.4% |
| 5 years | +14.06% | +13.05% | +14.60%to 30 Sep 2026 | 35 of 106 | +11.34% | +8.8% to +15.7% |
| 10 years | +15.11% | +14.09% | +12.65%to 30 Sep 2026 | 25 of 70 | +14.17% | +11.9% to +15.8% |
₹10,000 put in on 2 Jan 2013 is ₹89,060 at the NAV of 29 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load. Growth of ₹10,000 in the glossaryOver a year and longer, a return is the yearly rate. Benchmark: BSE Healthcare TRI, over the same days as the fund, or to the month end its cell names. Rank, median and middle half among the Direct plans of Sectoral / Thematic funds, each fund's return to its latest NAV on or before 29 Oct 2026.
At the month end, 30 Sep 2026
| Over | Fund | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. Benchmark return in the glossary |
|---|---|---|
| 1 year | +13.87% | +16.77% |
| 3 years | +17.69% | +21.25% |
| 5 years | +13.73% | +14.60% |
| 10 years | +15.51% | +12.65% |
| Since launch | +17.35% | +14.79% |
Benchmark: BSE Healthcare TRI. Both as the fund house states them for the month.
Return in each calendar year
- Fund, Direct GrowthCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
- Loss
Highest year to Dec 2020, +67.9%; lowest year to Dec 2016, −9.7%
Nippon India Pharma Fund SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 29 Oct 2026SIP calculator
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. Amount invested in the glossary | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. Value today in the glossary | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. SIP return (XIRR) in the glossary | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. SIP return after stamp duty in the glossary | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. Stamp duty paid in the glossary |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,26,342₹1,26,336 after stamp duty | +10.06% | +10.05% | ₹6 | |
| 3 years36 instalments | ₹3,60,000 | ₹4,18,532₹4,18,511 after stamp duty | +10.07% | +10.07% | ₹18 | |
| 5 years60 instalments | ₹6,00,000 | ₹8,90,895₹8,90,850 after stamp duty | +15.85% | +15.84% | ₹30 | |
| 10 years120 instalments | ₹12,00,000 | ₹30,85,588₹30,85,525 after stamp duty | +17.98% | +17.98% | ₹38 | |
| Since Jan 2013165 instalments | ₹16,50,000 | ₹57,71,817₹57,71,754 after stamp duty | +16.74% | +16.74% | ₹38 |
A SIP that rises every year: Step-up SIP calculator
Rolling returns
Per cent a year, every window from 2 Jan 2013 to 29 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The lowest yearly return of any window of this length in the fund's history, one window starting on each day it priced. Lowest rolling return in the glossaryAverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history. Average rolling return in the glossaryHighestHighest rolling return. The highest yearly return of any window of this length in the fund's history. Highest rolling return in the glossaryEnded higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started. Windows that ended higher in the glossary
1 year3,154 windows−15.1%+20.0%+90.7%76.5%
3 years2,666 windows−1.3%+17.2%+32.1%98.6%
5 years2,173 windows0.0%+16.6%+32.1%100.0%
10 years941 windows+13.1%+16.2%+18.8%100.0%
Every 5 and 10-year window ended higher than it started.
Nippon India Pharma Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Regular over directDirect and regular plan cost gap. The regular plan's expense ratio less the direct plan's: what buying through a distributor costs each year, since both plans own the same portfolio. Direct and regular plan cost gap in the glossary
- 0.86 ptsA year, on 26 Oct 2026
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies. Expense ratio, 30-day average in the glossary
- 0.99%Over the last 30 days filed
- Regular, 30-day average
- 1.84%Over the last 30 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan highest 1.48%, Apr 2026.Direct plan lowest 0.80%, Apr 2021.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. Base expense ratio in the glossary | 0.79% | 1.52% |
| Brokerage | 0.02% | 0.02% |
| Transaction costs | None | None |
| Statutory levies | 0.18% | 0.31% |
Per cent of assets a year, filed for 26 Oct 2026. The parts add up to that day's total.
Exit load, in the fund house's words
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Buying and selling
- Lump-sum purchases
- Accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase. Minimum investment in the glossary
- ₹5,000
- Minimum top-up
- ₹1,000
- Minimum redemption
- ₹100
- SIP
- Accepted
- SIP dates
- 1st to 31st of a month
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold. Lock-in in the glossary
- None
- SIP minimum
- Rs.100/- per month (minimum 60 months) Rs.500/- per month (minimum 12 months) Rs.1000/- per month (minimum 6 months) Rs. 500/- per quarter (minimum 12 quarters) Rs.1500/- per quarter (minimum 4 quarters) Rs. 5000/- per year (minimum 2 years)
- SIP instalments, at least
- 60 months for Rs. 100 per month 12 months for Rs. 500 per month 6 months for Rs. 1,000 per month 12 quarters for Rs. 500 per quarter 4 quarters for Rs. 1500 per quarter 2 years for Rs. 5000 per Year
As listed for this plan on 30 Oct 2026.
How Nippon India Pharma Fund is taxed
Taxed as an equity fund where it keeps 65% or more in shares of listed Indian companies: gains on units held over 12 months are taxed at 12.5% above ₹1.25 lakh a year, and gains on units held 12 months or less at 20%. Otherwise, gains on units held over 24 months are taxed at 12.5%, and gains on units held 24 months or less at the income tax slab rate.
IDCW payouts are added to the holder's income and taxed at the income tax slab rate. The fund deducts 10% tax at source for a resident when its payouts to them in a year counted from April to March are above ₹10,000.
Rules in force from 1 Apr 2025, checked 27 Oct 2026. Surcharge and cess are not included.
Nippon India Pharma Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹9,272 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors. Share of assets in the direct plans in the glossary
- 27.2%Of the quarter's average
Average assets by quarter, by plan
- Regular plans
- Direct plans
The latest quarter is the largest since the quarter to Jun 2010.
Assets at each month end
Highest ₹9,479 Cr, Aug 2026.Lowest ₹2,190 Cr, Mar 2020.
Nippon India Pharma Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. Large, mid and small cap in the glossary | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. Weight in the fund in the glossary | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. Held since in the glossary | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 11.71% | 1,072.95 | 59,06,349 | Sep 2012or earlier |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 7.10% | 651.11 | 7,00,754 | Sep 2012or earlier |
| LupinPharmaceuticals & Biotechnology | Mid cap105th | 6.17% | 565.21 | 27,83,991 | Sep 2012or earlier |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 6.01% | 551.19 | 40,95,054 | Sep 2012or earlier |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 5.45% | 499.33 | 40,49,746 | Sep 2012or earlier |
| Apollo Hospitals EnterpriseHealthcare Services | Large cap97th | 4.89% | 448.12 | 5,48,795 | Sep 2020 |
| Mankind PharmaPharmaceuticals & Biotechnology | Mid cap119th | 4.38% | 401.50 | 16,03,562 | Apr 2023 |
| Sai Life SciencesPharmaceuticals & Biotechnology | Small cap329th | 3.92% | 359.13 | 23,55,745 | Dec 2024 |
| Ajanta PharmaPharmaceuticals & Biotechnology | Mid cap236th | 3.61% | 330.91 | 9,13,918 | Apr 2022 |
| GlaxoSmithKline PharmaceuticalsPharmaceuticals & Biotechnology | Mid cap221st | 3.11% | 285.09 | 10,29,460 | Aug 2022 |
| IPCA LaboratoriesPharmaceuticals & Biotechnology | Mid cap229th | 2.87% | 262.99 | 13,64,742 | Nov 2024 |
| Max Healthcare InstituteHealthcare Services | Mid cap111th | 2.70% | 247.15 | 26,58,082 | Oct 2025 |
| Vijaya Diagnostic CentreHealthcare Services | Small cap523rd | 2.62% | 240.33 | 16,71,618 | Sep 2021 |
| Gland PharmaPharmaceuticals & Biotechnology | Small cap261st | 2.53% | 232.11 | 8,00,549 | Nov 2020 |
| Medplus Health ServicesRetailing | Small cap555th | 2.53% | 232.18 | 35,45,229 | Nov 2022 |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| Triparty Repo | 2.81% | 257.79 |
| Net Current Assets | −0.14% | −11.49 |
| Cash Margin - CCIL | 0.02% | 1.50 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions. Largest holding in the glossary
- 11.71%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions. Top 5 holdings in the glossary
- 36.44%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions. Top 10 holdings in the glossary
- 56.35%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights. Effective number of holdings in the glossary
- 20.9Taken over 97.31% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought. Asset allocation in the glossary- Indian shares97.31%
- Cash and receivables2.69%
Per cent of the fund's net assets.
Large, mid and small cap
- Large cap30.53%Category 49.50%
- Mid cap40.10%Category 21.62%
- Small cap28.82%Category 26.68%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026. Shares not on the list: 0.54% of the fund. Category is the average of 249 Sectoral / Thematic funds.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets. Sector weight in the glossary2sectors
- Healthcare94.78%Category 12.70%
- Consumer Services2.53%Category 5.61%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026. Category is the average of 254 Sectoral / Thematic funds. Category average. The sector's weight, less the futures sold on it, averaged over the 254 Sectoral / Thematic funds that disclosed a portfolio for Sep 2026. A fund holding none of the sector counts as 0.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare35 companies | 94.78% | 95.48% | 94.63% | 94.46% | 94.30% | 94.92% | 95.59% | 95.98% | 95.28% | 93.83% | 96.00% | 96.35% | |
| Consumer Services1 company | 2.53% | 2.51% | 2.69% | 3.18% | 3.68% | 3.78% | 3.86% | 3.70% | 3.68% | 3.54% | 3.47% | 3.32% | |
| Financial Services | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Capital Goods | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Automobile And Auto Components | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Information Technology | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Fast Moving Consumer Goods | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Consumer Durables | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Oil Gas & Consumable Fuels | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Telecommunication | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Power | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Services | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before. New positions in the glossary
- 0
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date. Sold out in the glossary
- 0
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth. Added to in the glossary
- 1
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth. Trimmed in the glossary
- 2
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price. Unchanged in the glossary
- 33
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month. Traded at least in the glossary
- 0.00%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it. Weight that moved in the glossary
- 2.66%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). What changed in the glossary | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. Change in weight in the glossary | ||||
|---|---|---|---|---|---|
| Abbott India | Added | 2.32% | 2.13% | +0.19 pts | +420 |
| Sai Life Sciences | Trimmed | 3.92% | 3.94% | −0.02 pts | −2,00,000 |
| Indoco Remedies | Trimmed | 0.48% | 0.47% | +0.01 pts | −1,54,909 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries | 12.67% | 13.55% | 13.02% | 12.67% | 13.08% | 13.92% | 13.85%Added | 13.35% | 12.78%Cut | 13.31% | 12.37%Cut | 11.71% |
 Divi's Laboratories | 8.07% | 6.90%Cut | 6.58%Cut | 6.54% | 6.56% | 6.41% | 6.61% | 5.80%Cut | 5.46% | 6.52% | 7.00%Cut | 7.10% |
 Lupin | 7.26% | 7.59% | 7.36%Cut | 7.88% | 7.99% | 8.45% | 7.95% | 7.31%Cut | 7.45% | 7.25% | 6.43% | 6.17% |
 Cipla | 6.29% | 6.33% | 6.39% | 5.88% | 5.67% | 5.42% | 5.47% | 6.16%Added | 6.15% | 6.03% | 6.09%Added | 6.01% |
 Dr. Reddy's Laboratories | 5.62% | 5.83% | 6.02% | 6.06% | 5.81%Cut | 5.96% | 7.04%Added | 6.72% | 6.68% | 5.01%Cut | 4.93% | 5.45% |
 Apollo Hospitals Enterprise | 5.97% | 5.63% | 5.53% | 5.73% | 5.17%Cut | 5.15% | 5.01% | 5.20% | 5.27% | 5.30% | 5.15% | 4.89% |
 Mankind Pharma | 2.16% | 2.02% | 2.01% | 2.45%Added | 3.06%Added | 2.87% | 3.04% | 3.94%Added | 4.03% | 3.74%Cut | 4.09%Added | 4.38% |
 Sai Life Sciences | 2.81% | 2.67% | 2.81% | 2.71% | 3.07% | 3.15% | 3.27% | 3.43% | 3.49% | 3.62% | 3.94% | 3.92%Cut |
 Ajanta Pharma | 2.83% | 2.90% | 3.21% | 3.39% | 3.41%Cut | 3.36% | 3.19% | 3.21% | 3.46%Cut | 3.41% | 3.47% | 3.61% |
 GlaxoSmithKline Pharmaceuticals | 2.87% | 2.77% | 2.73% | 2.78% | 2.83% | 2.64% | 2.55% | 2.34% | 2.47% | 2.66%Added | 3.31%Added | 3.11% |
 IPCA Laboratories | 1.50%Added | 1.93%Added | 2.05%Added | 2.55%Added | 2.51% | 2.77% | 2.50% | 2.41% | 2.57% | 2.57% | 2.84% | 2.87% |
 Max Healthcare Institute | 1.23%Bought | 1.23% | 1.13% | 1.51%Added | 3.49%Added | 3.24% | 3.16% | 2.97% | 3.32% | 3.15% | 2.92% | 2.70% |
 Vijaya Diagnostic Centre | 3.42% | 3.41% | 3.71% | 3.51% | 3.49% | 3.15% | 3.36%Cut | 3.21%Cut | 2.80%Cut | 2.42%Cut | 2.68% | 2.62% |
 Gland Pharma | 3.05% | 2.75% | 1.67%Cut | 1.88% | 1.76% | 1.72% | 1.68% | 2.09% | 2.21% | 2.16% | 2.44% | 2.53% |
 Medplus Health Services | 3.32% | 3.47% | 3.54% | 3.68% | 3.70% | 3.86% | 3.78% | 3.68%Cut | 3.18% | 2.69% | 2.51% | 2.53% |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it. Portfolio turnover in the glossary
Highest 17.0% in Aug 2026
Risk ratios
NAV to 29 Oct 2026
Each bar runs from the lowest to the highest figure among the Direct plans of Sectoral / Thematic funds (130 funds) over the same 3 years; the tick is their average and the dot this fund.
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves. Standard deviation in the glossary15.07%
12.76%Lowest17.49%Average of 138 funds31.25%Highest
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure. Downside deviation in the glossary8.42%
5.67%Lowest10.73%Average of 138 funds16.26%Highest
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV. Sharpe ratio in the glossary0.77
−0.56Lowest0.47Average of 138 funds1.19Highest
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down. Sortino ratio in the glossary1.25
−0.68Lowest0.75Average of 138 funds2.32Highest
Against BSE Healthcare TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less. Beta in the glossary0.89
0.63Lowest0.93Average1.21Highest
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100. R-squared in the glossary94.5
42.9Lowest87.3Average98.2Highest
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together). Correlation in the glossary0.97
0.66Lowest0.93Average0.99Highest
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months. Upside capture in the glossary88.6%
65.5%Lowest99.0%Average134.6%Highest
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months. Downside capture in the glossary91.4%
45.6%Lowest87.9%Average118.1%Highest
Information ratioInformation ratio. The fund's return above its benchmark, divided by how much that difference varied, as stated by the fund house. Information ratio in the glossaryTo 30 Sep 2026−0.79
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. Largest fall in the glossary | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. Back at the high in the glossary |
|---|---|---|---|---|
| 1 year | −9.56% | 31 Aug 2026 | 23 Oct 2026 | Not yet |
| 3 years | −14.72% | 2 Jan 2025 | 28 Feb 2025 | 24 Jul 2025 |
| 5 years | −18.74% | 31 Dec 2021 | 17 Jun 2022 | 21 Jun 2023 |
| 10 years | −21.18% | 19 Feb 2020 | 23 Mar 2020 | 9 Apr 2020 |
| Since Jan 2013 | −24.02% | 30 Oct 2015 | 29 May 2017 | 17 Aug 2018 |
Risk level by month
| Months | Fund | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. Benchmark's risk level in the glossary |
|---|---|---|
| Oct 2021 to Aug 202659 months | Very High | Very HighBSE Healthcare TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
Nippon India Pharma Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. Return in the manager's time in the glossary | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. Benchmark over the same days in the glossary | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. Difference from the benchmark in the glossary | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. Portfolio changed after the handover in the glossary | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. Portfolio changed before the handover in the glossary | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. Assets the manager runs in the glossary | ||
|---|---|---|---|---|---|---|---|---|
| Sailesh Raj BhanPrimary | Jun 2004 | – | – | – | – | – | 3 | ₹1,14,229 Cr₹9,166 Cr alone |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | |||||
|---|---|---|---|---|---|
| Nippon India Multi Cap FundSailesh Raj Bhan | Mar 2005 | – | – | – | ₹53,767 Cr |
| Nippon India Large Cap FundSailesh Raj Bhan | Aug 2007 | – | – | – | ₹51,296 Cr |
The ten largest by assets, by manager. Returns are the direct plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. Portfolio overlap in the glossary | Shared holdings. The number of securities both funds hold, cash and futures left out. Shared holdings in the glossary | |
|---|---|---|
| Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 63.77% | 28 |
| ITI Pharma and Healthcare FundITI Mutual Fund | 57.57% | 20 |
| Bandhan Healthcare FundBandhan Mutual Fund | 54.90% | 20 |
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 54.34% | 19 |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 54.21% | 20 |
| Tata India Pharma & Healthcare FundTata Mutual Fund | 52.18% | 22 |
| UTI Healthcare FundUTI Mutual Fund | 51.27% | 22 |
| Baroda BNP Paribas Health and Wellness FundBaroda BNP Paribas Mutual Fund | 48.55% | 19 |
| WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund | 47.34% | 20 |
| Kotak Healthcare FundKotak Mahindra Mutual Fund | 46.73% | 17 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Overlap with the fund house's other funds
| Nippon India MNC FundNippon India Mutual Fund | 11.86% |
| Nippon India Growth Mid Cap FundNippon India Mutual Fund | 10.22% |
| Nippon India Multi Cap FundNippon India Mutual Fund | 9.66% |
| Nippon India Large Cap FundNippon India Mutual Fund | 7.42% |
| Nippon India Vision Large & Mid Cap FundNippon India Mutual Fund | 7.37% |
| Nippon India Quant FundNippon India Mutual Fund | 6.28% |
| Nippon India Innovation FundNippon India Mutual Fund | 6.14% |
| Nippon India ELSS Tax Saver FundNippon India Mutual Fund | 6.01% |
| Nippon India Small Cap FundNippon India Mutual Fund | 5.98% |
| Nippon India Active Momentum FundNippon India Mutual Fund | 5.03% |
As the fund house states it, for Sep 2026.
Nippon India Pharma Fund dividend history
IDCW (income distribution cum capital withdrawal), once called a dividend: rupees per unit, paid to holders on the record date and taken out of the NAV. Paid by the fund's Direct IDCW plan.Every fund's payouts
Paid per unit, the latest payouts
- Paid per unitIDCW payout. Rupees paid out per unit to holders on the record date; the money comes out of the fund, so the plan's NAV falls by the same amount. IDCW payout in the glossary
Largest ₹13.00 a unit, Feb 2025.
Every payout
| IDCW yield. A payout as a share of the plan's NAV on the record date, before the NAV fell by the amount paid. IDCW yield in the glossary | NAV before | NAV after | ||
|---|---|---|---|---|
| 5 Feb 2026 | ₹12.00 | 7.30% | ₹164.2774 | ₹152.0094 |
| 20 Feb 2025 | ₹13.00 | 7.76% | ₹167.5456 | ₹152.2187 |
| 23 Feb 2024 | ₹10.00 | 6.11% | ₹163.7545 | ₹152.7410 |
| 25 Feb 2022 | ₹3.50 | 3.32% | ₹105.5234 | ₹103.0705 |
| 26 Feb 2021 | ₹6.00 | 6.15% | ₹97.5421 | ₹92.9310 |
| 28 Feb 2020 | ₹3.984338 | 5.98% | ₹66.6591 | ₹61.3193 |
| 1 Mar 2019 | ₹4.427042 | 6.47% | ₹68.4626 | ₹63.7031 |
| 1 Mar 2018 | ₹6.00 | 8.60% | ₹69.7751 | ₹63.2904 |
| 3 Mar 2017 | ₹6.50 | 8.86% | ₹73.3684 | ₹66.8984 |
| 4 Mar 2016 | ₹7.00 | 8.68% | ₹80.6107 | ₹73.4340 |
| 30 Jan 2015 | ₹7.00 | 8.47% | ₹82.6165 | ₹75.3064 |
| 14 Feb 2014 | ₹4.50 | 7.80% | ₹57.7030 | ₹53.2298 |
All 12 payouts since 14 Feb 2014.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Fund details
Objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.
Asset allocation
- Equity and Equity related Instruments of companies in Pharma Sector – 80%-100%, Equity and Equity Related securities of companies other than those engaged in pharma sector - 0% - 20%, Debt Securities & Money Market instruments - 0% - 20%, & Units issued by REITs and InvITs – 0%-10%
Type of scheme
Open
- Stated category
- Sectoral Fund
- Benchmark
- BSE Healthcare TRI
- Risk level at launch
- High
- New fund offer
- 10 May 2004 to 26 May 2004
- Units first allotted
- 5 Jun 2004
- Open for sale again
- 8 Jun 2004
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹5,000
Plans and codes
| Plan | AMFI code | ISIN | ISIN, reinvestment | MUTF_IN | First NAV |
|---|---|---|---|---|---|
| Direct Growth | 118759 | INF204K01I50 | NIPP_INDI_PHAR_12HWAIJ | 2 Jan 2013 | |
| Regular Growth | 102431 | INF204K01968 | NIPP_INDI_PHAR_LS0FN2 | 3 Apr 2006 | |
| Direct IDCW | 118756 | INF204K01I35 | INF204K01I43 | NIPP_INDI_PHAR_VK2IKI | 2 Jan 2013 |
| Regular IDCW | 102433 | INF204K01935 | INF204K01943 | NIPP_INDI_PHAR_VQHVHS | 3 Apr 2006 |
This fund
- Scheme information documentThe fund's objective, terms, costs and risks in full
Factsheet
- Fundamentals \ E-Factsheet: October 2026Nippon India Mutual Fund, Sep 2026
Statement of additional information
- SAI Nippon India Mutual FundNippon India Mutual Fund, Oct 2026
Annual report
- Abridged Scheme Account 2025-2026 - 1. Consolidated Equity & Fund of Fund SchemesNippon India Mutual Fund, Mar 2026
- Abridged Scheme Account 2025-2026 - 2. Consolidated Debt SchemesNippon India Mutual Fund, Mar 2026
- Abridged Scheme Account 2025-2026 - 3. Consolidated Exchange Traded FundsNippon India Mutual Fund, Mar 2026
- Abridged Scheme Account 2025-2026 - 4.Consolidate Interval Funds and Fixed Maturity PlansNippon India Mutual Fund, Mar 2026
Riskometer disclosure
- Changes in Riskometers in FY26Nippon India Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Portfolio OverlapNippon India Mutual Fund, Sep 2026
- Portfolio-Overlap-30-Sep-2026Nippon India Mutual Fund, Sep 2026